Point of Care Testing for Hepatitis B virus Market Size (2024 –2030)

The Global Point of Care Testing for Hepatitis B Virus Market was estimated to be worth USD 583.94 Million in 2023 and is projected to reach a value of USD 907.43 Million by 2030, growing at a CAGR of 6.5% during the forecast period 2024-2030.

Point of Care Testing (POCT) for the hepatitis B virus (HBV) is a rapid diagnostic test that can be performed on-site by patients themselves, without the need for sophisticated lab equipment or highly skilled personnel. It's similar to getting a quick test for strep throat at your doctor's office rather than having a lab test performed. Because POCT provides results more quickly, at a lower cost, and with greater convenience for patients and healthcare providers, it can be very beneficial. Surprisingly, though, 90% of hepatitis B patients are unaware that they have the illness. This is a serious issue because blood tests required to screen for hepatitis B are not easily accessible to many people, even though the disease can be fatal. We can facilitate testing by offering point-of-care testing, particularly in areas without access to sophisticated labs. Rather than needing to travel to a large hospital, individuals could get tested at home or in their local community clinics. However, despite the approval of some hepatitis B tests, their widespread use has not yet been realized in many countries. To identify more cases of hepatitis B and provide necessary treatment, governments and healthcare systems must begin utilizing these tests more frequently. This can save lives and help avoid major health issues.

Key Market Insights:

Rapid diagnostic tests (RDTs) account for around 65% of the point-of-care testing market for HBV, owing to their simplicity, portability, and ability to provide quick results.

The North American region constitutes approximately 30% of the demand for point-of-care HBV testing, driven by the high prevalence of hepatitis B in countries like China, India, and Southeast Asia.

In terms of end-users, community healthcare settings (clinics, mobile testing units, etc.) account for around 35% of the point-of-care HBV testing market share, reflecting the growing emphasis on decentralized and accessible testing services.

The adoption of multiplexed point-of-care tests capable of detecting multiple infectious diseases, including HBV, is growing at a rate of approximately 12% annually, driven by the need for comprehensive and cost-effective screening solutions.

Global Point of Care Testing for Hepatitis B virus Market Drivers:

The market for testing services for the hepatitis B virus is being driven by the growing need for early diagnosis.

The hepatitis B virus (HBV) is a common viral infection that affects approximately 292 million individuals globally. In order to prevent the disease from getting worse, early detection and treatment are essential. It can result in dangerous diseases like liver cancer and cirrhosis if left untreated. The need for HBV testing and monitoring has increased due to the rising number of cases. Point-of-care testing (POCT) and nucleic acid testing (NAT) are two examples of new diagnostic technologies that have improved the speed, accuracy, and ease of HBV infection detection. This implies that we can more accurately diagnose and treat HBV. Governments from all around the world have started initiatives to address HBV and increase access to care and screening. The need for testing is anticipated to increase as the World Health Organization (WHO) seeks to eradicate HBV as a threat to public health by 2030. More people are requesting testing as a result of public education campaigns that have increased understanding of the significance of HBV diagnosis and treatment. The need for trustworthy diagnostic tests to meet the expanding demand for HBV screening is highlighted by this increased demand.

Growth of cutting-edge diagnostic tools supporting the market for chronic hepatitis B virus testing.

There are various tests available to detect the presence of the hepatitis B virus (HBV). One test, known as the HBsAg test, looks for a portion of the virus in the blood to determine whether an infection is still present. Another test that looks for antibodies indicating current or previous infection is the anti-HBc test. To find out if someone is immune to HBV or received the vaccination, there is also the anti-HBs test. The viral load test quantifies the amount of virus in the blood, whereas the HBeAg test indicates whether the virus is actively spreading. Tests for liver function, such as AST and ALT, can also detect liver damage. The WHO has evaluated and approved the Biomerieux VIKIA® HBs Ag test, demonstrating its dependability in the diagnosis of HBV infection. It is a rapid test.

Point of Care Testing for Hepatitis B virus Market Challenges and Restraints:

Testing for chronic HBV infections can be difficult to obtain in developing nations due to factors like a lack of healthcare facilities, a lack of funding, and a general lack of awareness of the illness. Furthermore, some people may not be able to pay for these tests due to their high cost, particularly those without adequate insurance. Test results can occasionally be inaccurate, reporting a false positive (indicating that you have HBV when you don't) or false negative (indicating that you don't have HBV when you do). Delays in receiving the right diagnosis and care may result from this. Additionally, some people may choose not to get tested or treated out of fear of receiving unfavorable judgment or treatment due to their HBV. HBV is stigmatized in some cultures, which may discourage people from seeking treatment. Fewer people may get tested as a result of ignorance about the risk factors and the significance of diagnosis and treatment, which would exacerbate the already serious situation. Treatments for HBV may not be effective for everyone and may have harmful side effects, which can make managing the illness difficult.

Point of Care Testing for Hepatitis B virus Market Opportunities:

There are numerous prospects for expansion and enhancement in the Hepatitis B virus (HBV) Point of Care Testing (POCT) market. There is an increase in home-based testing, which offers patients greater privacy and convenience. Testing is now more accurate and thorough thanks to advancements in cassette and card technology. Procedures can be streamlined by integrating HBV POCT devices with COVID-19 testing systems. POCT devices can aid in achieving the critical goals of early detection and monitoring. Underdeveloped areas with poor access to healthcare offer unexplored prospects for market growth. In general, the HBV POCT market offers opportunities for improvement, growth, and patient care.

POINT OF CARE TESTING FOR HEPATITIS B VIRUS MARKET REPORT COVERAGE:

Global Point of Care Testing for Hepatitis B Virus Market Segmentation: By Product Type

• Cassettes/Cards

• Strips

Because they provide a number of benefits over strips, the cassette and card industries are flourishing. Multiple parameters can be tested simultaneously with cassettes or cards, offering a more thorough testing experience. They frequently have integrated controls and sample-collection tools, which improve the precision and dependability of test findings. In addition, cassettes and cards generally have higher sensitivity and specificity than strips, which means that they can identify HBV infection at lower concentrations and yield more dependable results. This makes them perfect for HBV infection early detection and monitoring. However, strips continue to command the largest share of the market. They are easier to use in environments with limited resources because they are less complicated and more reasonably priced than cassettes or cards. Although strips are frequently used for quick screening, they might not be as accurate and comprehensive in terms of testing as cassettes or cards.

Global Point of Care Testing for Hepatitis B Virus Market Segmentation: By End Users

• Hospitals

• Diagnostic Centers

• Clinics

• Home Care

The growing need for decentralized healthcare and home-based testing options is fueling the industry's explosive growth in home care. Patients would rather monitor their HBV status in privacy and convenience at home rather than make frequent trips to the doctor. Hospitals continue to be the market leader for HBV testing in the interim. Hospitals are essential for HBV testing because of their large patient populations and an array of medical services. They frequently carry out point-of-care testing, taking advantage of specialized labs and knowledgeable personnel to guarantee precise and fast results. Hospitals are also outfitted to manage complicated cases and offer complete care to patients with HBV.

Global Point of Care Testing for Hepatitis B Virus Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East and Africa

HBV point-of-care testing (POCT) is most popular in North America due to the region's sophisticated healthcare system, high healthcare spending, and concentration of major industry players. The need for POCT devices is fueled by the high incidence of HBV in the area. The government's encouragement of early HBV detection and its favorable reimbursement policies also contribute to North America's market dominance. Due to Europe's developed healthcare system and high level of HBV awareness, the market for HBV POCT is expanding quickly. Early detection of infectious diseases like HBV and preventive healthcare are given top priority in the region. Modern POCT technology and the existence of significant market players both contribute to Europe's dominant position in the industry.

COVID-19 Impact on the Global Point of Care Testing for Hepatitis B virus Market:

The worldwide market for point-of-care testing (POCT) for the hepatitis B virus (HBV) has been adversely impacted by the COVID-19 pandemic. Accessing HBV testing and treatment has become more difficult for people due to lockdowns, travel restrictions, and overworked healthcare systems. Because of these factors—missed or delayed diagnoses, interrupted treatments, and a lack of preventative measures like vaccination—there is a higher chance that HBV will spread and cause major health issues. These difficulties have resulted in a decline in the market for HBV POCT devices, which are now more expensive and less readily available. Furthermore, compared to COVID-19, viral hepatitis is not as well-known among patients, medical professionals, and policymakers. Innovation in HBV POCT devices is required to address these problems. Some of these innovations include ensuring the devices' quality and reliability in various environments, making them easier to use in remote areas, and compatibility with COVID-19 testing systems.

Latest Trend/Development:

The market for Hepatitis B virus (HBV) Point of Care Testing (POCT) is being shaped by a number of innovative trends and advancements. First, efforts are being made to improve technology by making new gadgets more precise and sensitive. Additionally, these gadgets are connected to digital health platforms, which facilitates remote patient data tracking and care delivery. In order to increase accessibility, it is also important to make these gadgets simple to use for everyone, including non-medical professionals. More people will be able to get tested as testing services spread outside of hospitals and into locations like pharmacies and mobile clinics. The ability to take multiple tests at once, known as multiplex testing, is also gaining popularity. Finally, in order to guarantee the validity of the tests, quality assurance procedures are being implemented. The goal of these trends is to improve HBV testing accessibility, ease of use, and reliability for all.

Key Players:

1. Abbott Laboratories

2. Roche Diagnostics

3. bioMérieux SA

4. Danaher Corporation

5. Qiagen N.V

6. Siemens Healthineers AG

7. SD Biosensor Inc

8. Alere Inc

9. Biomedicglobal

10. Meridian Bioscience Inc

Market News:

• Abbott Laboratories and DialSafe, a top supplier of digital health solutions, announced a strategic partnership in December 2022 with the goal of creating a comprehensive point-of-care testing platform for infectious diseases, such as hepatitis B. The partnership seeks to improve patient outcomes and test accessibility by fusing DialSafe's digital health technologies with Abbott's diagnostic expertise.

• The Indian business MolBio Diagnostics, which specializes in point-of-care molecular diagnostics, was purchased by Roche Diagnostics in January 2023. Roche made the acquisition as part of a plan to increase its market share in the quickly expanding point-of-care testing industry, especially in developing nations where the prevalence of infectious diseases like hepatitis B is high.